Preparation and characterization of spironolactone solid dispersions using hydrophilic carriers

Asian Journal of Pharmaceutical Sciences

Volumn 7, Issue 1, 2012, Pages 40-49

  Shah, Shreya ^a   Joshi, Sachi ^a   Lin, S ^a   Madan, P L ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

Dissolution rate; Equilibrium solubility; Poloxamer 407; Polyvinylpyrrolidone; Spironolactone solid dispersions

Indexed keywords

HYDROPHILIC CARRIER; MACROGOL; NANOCARRIER; POLOXAMER; POVIDONE; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; IN VITRO STUDY; INFRARED SPECTROSCOPY; SOLID DISPERSION; X RAY DIFFRACTION;

EID: 84871453396     PISSN: 18180876     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Chawla G, Bansal AK. Improved dissolution of a poorly water soluble drug in solid dispersions with polymeric and non-polymeric hydrophilic additives. Acta Pharm. 2008,58: 257-274.
2. Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci. 1971, 60: 1281-302.
3. Dhirendra K, Lewis S, Udupa N, et al. Solid dispersions: a review. Pak J Pharm Sci. 2009, 22: 234-246.
4. Craig DQ. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm. 2002, 231: 131-144.
5. Van den Mooter G, Augustijns P, Blaton N, et al. Physicochemical characterization of solid dispersions of temazepam with polyethylene glycol 6000 and PVP K30. Int J Pharm. 1998, 164: 67-80.
6. Chen Y, Zhang GG. Neilly J, et al. Enhancing the bioavailability of ABT-963 using solid dispersion containing PluronicF-68. Int J Pharm. 2004, 286: 69-80.
7. Vyas V, Sancheti P, Karekar P, et al. Physicochemical characterization of solid dispersion systems of tadalafil with poloxamer 407. Acta Pharm. 2009, 59: 453-461.
8. Bonlokke L, Hovgaard L, Kristensen HG, et al. Direct estimation of the in vivo dissolution of spironolactone, in two particle size ranges, using the single-pass perfusion technique (Loc-I-Gut) in humans. Eur J Pharm Sci. 2001,12: 239-250.
9. Clarke JM, Ramsay LE, Shelton JR, et al. Factors influencing comparative bioavailability of spironolactone tablets. J Pharm Sci. 1977, 66: 1429-1432.
10. McInnes GT, Asbury MJ, Ramsay LE, et al. Effect of micronization on the bioavailability and pharmacologic activity ofspironolactone. J Clin Pharmacol. 1982, 22:410-417.
11. Kaukonen A, Kilpelainen I, Mannermaa J. Water-soluble β-cyclodextrins in paediatric oral solutions of spironolactone:solubilization and stability of spironolactone in solutions of β-cyclodextrin derivatives. Int J Pharm. 1997, 159:.
12. Uchino T, Yasuno N, Yanagihara Y, et al. Solid dispersion of spironolactone with porous silica prepared by the solvent method. Pharmazie. 2007, 62: 599-603.
13. Yassin A, Alanazi F, El-Badry M, et al. "Preparation and characterization of spironolactone-loaded gelucire microparticles using spray-drying technique. Drug Dev Ind Pharm.2009, 35: 297-304.
14. Geneidi AS, Hamacher H. Enhancement of dissolution rates of spironolactone and diazepam via polyols and PEG solid dispersion system. Farm Ind. 1980, 42: 401-404.
15. Higuchi T, Connors K. Phase solubility techniques. Adv Anal Chem Instrm. 1965, 4: 212-217.
16. Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol. 1975, 27: 48-49.
17. Abdul-Fattah AM, Bhargava HN. Preparation and in vitro evaluation of solid dispersions of halofantrine. Int J Pharm. 2002, 235: 17-33.
18. Bhole P, Patil V. Enhancement of water solubility of felodipine by preparing solid dispersion using polyethylene glycol 6000 and poly-vinyl alcohol. Asian J Pharm Sci. 2009, 3: 240-244.
19. Chutimaworapan S, Ritthidej GC, Yonemochi E, et al. Effect of water-soluble carriers on dissolution characteristics.
20. Craig DQ. Polyethylene glycols and drug release. Drug Dev Ind Pharm. 1990, 16: 2501-2526.
21. Newa M, Bhandari KH, Xun Li D, et al. Preparation and evaluation of immediate release ibuprofen solid dispersions using polyethylene glycol 4000. Biol Pharm Bull. 2008, 31:939-945.
22. Gines, JM, Arias MJ, Holgado MA, et al. Dissolution rate study of fresh and aging triamterene-urea solid dispersions. Drug Dev Ind Pharm. 1994, 20: 2729-2740.
23. Liu D, Fei X, Wang S, et al. Increasing solubility and dissolution rate of drugs via eutectic mixtures: itraconazole-poloxamer 188 system. Asian J Pharm Sci. 2006, 1:213-221.
24. Newa M, Bhandari KH, Xun LD, et al. Preparation, characterization and in vivo evaluation of ibuprofen binary solid dispersions with poloxamer 188. Int J Pharm. 2007,343: 228-237.
25. Shah T, Amin A, Parikh J, et al. Process optimization and characterization of poloxamer solid dispersions of a poorlywater-soluble drug, AAPS Pharm Sci Tech 2007, 8: E1-E5.
26. Mehta A. Formulation and evaluation of solid dispersions of an anti-diabetic drug. Cur Trends Biotech Pharm. 2009,3: 76-84.
27. Junghanns JU, Muller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed. 2008, 3:295-309.
28. Muller RH, Jacobs C, Kayser OD. A novel formulation for poorly soluble and poorly bioavailable drugs. In: Rathbone M, Hadgraft J, Roberts M, editors. Modified-release drug delivery technology. New York: Marcel Dekker, 2003. p.135-150.
29. Mehta A. Formulation and evaluation of solid dispersions of an anti-diabetic drug. Cur Trends Biotech Pharmacy. 2009,3: 76-84.
30. Dong Y, Ng WK, Shen S, et al. Preparation and characterization of spironolactone nanoparticles by antisolvent precipitation. Int J Pharm. 2009, 375: 84-88.
31. Damian F, Blaton N, Naesens L, et al. Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and gelucire 44/14. Eur J Pharm Sci. 2000, 311-322.
32. Arias MJ, Gines JM, Moyano JR, et al. Dissolution properties and in vivo behaviour of triamterene in solid dispersions with polyethylene glycols. Pharm Acta Helv. 1996, 71: 229-235.
33. Habib M, Venkatram S, Hussain M. Fundamentals of solid dispersions. In: Habib M, editor. Pharmaceutical solid dispersion technology. Lancaster: Technomic Publishing Company, 2001. p. 7-36.
34. Kalaiselvan R, Mohanta G, Manna P, et al. Studies on mechanism of enhanced dissolution of albendazole solid dispersions with crystalline carriers. Indian J Pharm Sci. 2006, 68: 599-607.
35. Kennedy M, Hu J, Gao P, et al. Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study. Mol Pharm. 2008, 5:981-993.